Latest News for: daniel teper

Edit

NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the ...

Longview News-Journal 11 Dec 2023
INVO) in the first quarter of 2024. AVENTURA, Fla. and SARASOTA, Fla., Dec. 11, 2023 /PRNewswire/ -- NAYA Biosciences Inc ... Prospective Therapeutic Trials" section ... Daniel Teper ... About NAYA Biosciences ... Clinical trials are expected to start in 2024 ... 20549.
Edit

NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK™ Bispecific ...

Victoria Advocate 06 Dec 2023
INVO) in the first quarter of 2024. AVENTURA, Fla. and SARASOTA, Fla. and GALWAY, Ireland and SAN DIEGO, Dec. 6, 2023 /PRNewswire/ -- NAYA Biosciences Inc ... Daniel Teper ... Both companies will share the costs of manufacturing and preclinical assessments ... ....
Edit

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice ...

Longview News-Journal 10 Nov 2023
I look forward to working closely with Daniel and his leadership team on their mission to accelerate the development and commercialization of ... Daniel Teper, Chairman and CEO of NAYA Biosciences.
Edit

Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments

Longview News-Journal 24 Oct 2023
FinancialNewsMedia.com News Commentary. PALM BEACH, Fla., Oct ... They are referred to as relapse/refractory AML patients ... (NASDAQ ... Dr. Daniel Teper, currently Chairman & CEO of NAYA Biosciences, will be named Chairman & CEO of the combined company.
Edit

INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Traded Life ...

Longview News-Journal 23 Oct 2023
Daniel Teper, currently Chairman & CEO of NAYA Biosciences, will be named Chairman & CEO of the combined company ... Daniel Teper, Co-Founder, Chairman, and Chief Executive Officer of NAYA ...
Edit

Cytovia Therapeutics Presents New Data on CD38-Targeted Flex-NK™ Bispecific Antibody at 2022 American Society of ...

Victoria Advocate 09 Dec 2022
AVENTURA, Fla. and NATICK, Mass., Dec ... "We're delighted to see further progress on our CD38-targeted Flex-NK™ bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023," commented Cytovia CEO Dr. Daniel Teper.
Edit

Cytovia Therapeutics Presents New Data on TALEN® Gene-Edited iNK Cells and GPC3-Targeted Flex-NK™ Bispecific Antibodies ...

Longview News-Journal 07 Nov 2022
AVENTURA, Fla. and NATICK, Mass., Nov ... The data will be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting (SITC 2022) taking place in Boston, MA, and virtually November 8-12th, 2022 ... Daniel Teper ... Title ... Abstract Number. 177. Time.
Edit

Cytovia Therapeutics Mourns the Passing of Cancer Immunotherapy Industry Leader and COO Dr. Olivier Jean-Marie Gouédard

Victoria Advocate 06 Sep 2022
AVENTURA, Fla. and NATICK, Mass., Sept. 6, 2022 /PRNewswire/ -- Cytovia Therapeutics, Inc ... We are profoundly saddened by the news of our dear friend Olivier's passing. Dr ... "We want to recognize Dr ... Daniel Teper, CEO of Cytovia Therapeutics ... Dr ... ....
  • 1

Most Viewed

×